New project aims to develop low-cost device that can detect drug allergies within 30 minutes

NewsGuard 100/100 Score

Led by the Polytechnic Univeristy of Valencia, this project aims to develop a low-cost device that can detect drug allergies within just 30 minutes.

The Universitat Politècnica de València (Polytechnic University of Valencia, UPV) is at the helm of a new Horizon2020 research project to develop a low-cost biophotonic device that can detect drug allergies within 30 minutes. Going by the acronym "Cobiophad", short for Compact Biophotonic Platform for Drug Allergy Diagnosis, it also receives funding from the European Technology Platform Photonics 21.

The project will focus on the diagnosis of allergies to the beta-lactam antibiotic group, which includes penicillin, amoxicillin and cephalosporins and is the most prevalent drug allergy in Europe.

Project coordinator and researcher at the UPV's Interuniveristy Research Institute for Molecular Recognition and Technological Development (IDM), ángel Maquieira explains: "Current tests for drug allergies mainly take the form of in vivo testing and, although in vitro methods do already exist, they are not especially sensitive and can lead to imprecise diagnoses. They also analyse few allergens, are slow, taking between one and three hours, and expensive, costing around €30 per allergen".

Not only does Cobiophad aim to reduce the time and cost involved in diagnosing these allergies, but crucially it will ultimately improve the prescription of antibiotics. "This will contribute to improving the health and quality of life of the millions of Europeans that suffer from allergies to beta-lactam antibiotics, as well as to the sustainability of healty systems (Maquieira).

Also taking part in this project, which kicked off last month, are other research groups and companies from around Europe: Sintef (Norway), SONY (Austria), Optoel (Romania), Biotronics (UK), Eurexploit (UK), Dr. Fooke Laboratorien (Germany) and the UPV spin-off Das Photonics. As well as experts from Valencia's "La Fe" health research institute and Montpellier university hospital (France).

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer